AMD3465, a monomacrocyclic CXCR4 antagonist and potent HIV entry inhibitor
- PMID: 16011832
- DOI: 10.1016/j.bcp.2005.05.035
AMD3465, a monomacrocyclic CXCR4 antagonist and potent HIV entry inhibitor
Abstract
The chemokine receptors CCR5 and CXCR4 function as coreceptors for human immunodeficiency virus (HIV) and are attractive targets for the development of anti-HIV drugs. The most potent CXCR4 antagonists described until today are the bicyclams. The prototype compound, AMD3100, exhibits potent and selective anti-HIV activity against CXCR4-using (X4) viruses and showed antiviral efficacy in X4 HIV-1-infected persons in a phase II clinical trial. However, AMD3100 lacks oral bioavailability due to its high overall positive charge. Initial structure-activity relationship studies with bicyclam analogues suggested that the bis-macrocyclic structure was a prerequisite for anti-HIV activity. Now, we report that the N-pyridinylmethylene cyclam AMD3465, which lacks the structural constraints mentioned above, fully conserves all the biological properties of AMD3100. Like AMD3100, AMD3465 blocked the cell surface binding of both CXCL12 (the natural CXCR4 ligand), and the specific anti-CXCR4 monoclonal antibody 12G5. AMD3465 dose-dependently inhibited intracellular calcium signaling, chemotaxis, CXCR4 endocytosis and mitogen-activated protein kinase phosphorylation induced by CXCL12. Compared to the bicyclam AMD3100, AMD3465 was even 10-fold more effective as a CXCR4 antagonist, while showing no interaction whatsoever with CCR5. As expected, AMD3465 proved highly potent against X4 HIV strains (IC50: 1-10 nM), but completely failed to inhibit the replication of CCR5-using (R5) viruses. In conclusion, AMD3465 is a novel, monomacrocyclic anti-HIV agent that specifically blocks the interaction of HIV gp120 with CXCR4. Although oral bioavailability is not yet achieved, the monocyclams, with their decreased molecular charge as compared to the bicyclams, embody an important step forward in the design of oral CXCR4 antagonists that can be clinically used as anti-HIV drugs.
Similar articles
-
Pharmacology of AMD3465: a small molecule antagonist of the chemokine receptor CXCR4.Biochem Pharmacol. 2009 Oct 15;78(8):993-1000. doi: 10.1016/j.bcp.2009.06.010. Epub 2009 Jun 18. Biochem Pharmacol. 2009. PMID: 19540208
-
HIV chemokine receptor inhibitors as novel anti-HIV drugs.Cytokine Growth Factor Rev. 2005 Dec;16(6):659-77. doi: 10.1016/j.cytogfr.2005.05.009. Epub 2005 Jul 6. Cytokine Growth Factor Rev. 2005. PMID: 16005254 Review.
-
Inhibition of human immunodeficiency virus replication by a dual CCR5/CXCR4 antagonist.J Virol. 2004 Dec;78(23):12996-3006. doi: 10.1128/JVI.78.23.12996-13006.2004. J Virol. 2004. PMID: 15542651 Free PMC article.
-
Fluorescent CXCL12AF647 as a novel probe for nonradioactive CXCL12/CXCR4 cellular interaction studies.Cytometry A. 2004 Oct;61(2):178-88. doi: 10.1002/cyto.a.20070. Cytometry A. 2004. PMID: 15382150
-
Peptide-lead CXCR4 antagonists with high anti-HIV activity.Curr Opin Investig Drugs. 2001 Sep;2(9):1198-202. Curr Opin Investig Drugs. 2001. PMID: 11717804 Review.
Cited by
-
Modeling the SDF-1/CXCR4 protein using advanced artificial intelligence and antagonist screening for Japanese anchovy.Front Physiol. 2024 Feb 2;15:1349119. doi: 10.3389/fphys.2024.1349119. eCollection 2024. Front Physiol. 2024. PMID: 38370015 Free PMC article.
-
CXC chemokine receptor 4 (CXCR4) blockade in cancer treatment.J Cancer Res Clin Oncol. 2023 Aug;149(10):7945-7968. doi: 10.1007/s00432-022-04444-w. Epub 2023 Mar 11. J Cancer Res Clin Oncol. 2023. PMID: 36905421 Review.
-
Recent Advances in CXCL12/CXCR4 Antagonists and Nano-Based Drug Delivery Systems for Cancer Therapy.Pharmaceutics. 2022 Jul 25;14(8):1541. doi: 10.3390/pharmaceutics14081541. Pharmaceutics. 2022. PMID: 35893797 Free PMC article. Review.
-
PET Imaging Radiotracers of Chemokine Receptors.Molecules. 2021 Aug 26;26(17):5174. doi: 10.3390/molecules26175174. Molecules. 2021. PMID: 34500609 Free PMC article. Review.
-
HIV-1 Entry and Membrane Fusion Inhibitors.Viruses. 2021 Apr 23;13(5):735. doi: 10.3390/v13050735. Viruses. 2021. PMID: 33922579 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous